Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
30
VOR Quote, Financials, Valuation and Earnings
Last price:
$14.54
Seasonality move
:
-16.93%
Day range:
$13.39 - $15.27
52-week range:
$2.62 - $65.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.13x
Volume:
850.5K
Avg. volume:
2.6M
1-year change:
-16.92%
Market cap:
$99.4M
Revenue:
--
EPS (TTM):
-$381.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VOR
Vor Biopharma, Inc.
|
-- | -$4.10 | -- | -88.57% | $43.25 |
|
IBIO
iBio, Inc.
|
$25K | -$0.07 | -87.5% | -80.47% | $4.77 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OM
Outset Medical, Inc.
|
$30.7M | -$0.70 | -11.26% | -90.64% | $13.25 |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
-- | -$53.60 | -- | -928.79% | -- |
|
SNTI
Senti Biosciences, Inc.
|
$166.7K | -$0.57 | -- | -29.56% | $11.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VOR
Vor Biopharma, Inc.
|
$14.53 | $43.25 | $99.4M | -- | $0.00 | 0% | -- |
|
IBIO
iBio, Inc.
|
$1.87 | $4.77 | $42.1M | -- | $0.00 | 0% | 82.65x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
OM
Outset Medical, Inc.
|
$3.29 | $13.25 | $58.5M | -- | $0.00 | 0% | 0.65x |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
$0.64 | -- | $324.2K | -- | $0.00 | 0% | -- |
|
SNTI
Senti Biosciences, Inc.
|
$1.15 | $11.50 | $30.2M | -- | $0.00 | 0% | 3.27x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VOR
Vor Biopharma, Inc.
|
-0.14% | 21.965 | 0.92% | 9.05x |
|
IBIO
iBio, Inc.
|
5.55% | 1.666 | 19.65% | 8.21x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OM
Outset Medical, Inc.
|
40.94% | 2.357 | 38.74% | 5.74x |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
-- | 2.560 | -- | 2.60x |
|
SNTI
Senti Biosciences, Inc.
|
78.76% | -2.783 | 81.25% | 1.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VOR
Vor Biopharma, Inc.
|
-$2K | -$28.1M | -- | -- | -- | -$53.9M |
|
IBIO
iBio, Inc.
|
-$189K | -$6M | -75.48% | -88.23% | -5951% | -$5.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OM
Outset Medical, Inc.
|
$11.6M | -$15.8M | -35.38% | -81.05% | -53.73% | -$6.5M |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
-$1.1K | -$895.1K | -291.67% | -316.09% | -- | -$1.6M |
|
SNTI
Senti Biosciences, Inc.
|
-$904K | -$16.9M | -79.41% | -173.17% | -- | -$9.4M |
Vor Biopharma, Inc. vs. Competitors
-
Which has Higher Returns VOR or IBIO?
iBio, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of -5720%. Vor Biopharma, Inc.'s return on equity of -- beat iBio, Inc.'s return on equity of -88.23%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B IBIOiBio, Inc.-189% -$0.11 $59.3M -
What do Analysts Say About VOR or IBIO?
Vor Biopharma, Inc. has a consensus price target of $43.25, signalling upside risk potential of 197.66%. On the other hand iBio, Inc. has an analysts' consensus of $4.77 which suggests that it could grow by 154.9%. Given that Vor Biopharma, Inc. has higher upside potential than iBio, Inc., analysts believe Vor Biopharma, Inc. is more attractive than iBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.4 2 0 IBIOiBio, Inc.6 0 0 -
Is VOR or IBIO More Risky?
Vor Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.459%.
-
Which is a Better Dividend Stock VOR or IBIO?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or IBIO?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than iBio, Inc. quarterly revenues of $100K. Vor Biopharma, Inc.'s net income of -$812.7M is lower than iBio, Inc.'s net income of -$5.7M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 82.65x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M IBIOiBio, Inc.82.65x -- $100K -$5.7M
-
Which has Higher Returns VOR or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of -255.85%. Vor Biopharma, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About VOR or NBY?
Vor Biopharma, Inc. has a consensus price target of $43.25, signalling upside risk potential of 197.66%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Vor Biopharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Vor Biopharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.4 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is VOR or NBY More Risky?
Vor Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock VOR or NBY?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or NBY?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Vor Biopharma, Inc.'s net income of -$812.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns VOR or OM?
Outset Medical, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of -60.61%. Vor Biopharma, Inc.'s return on equity of -- beat Outset Medical, Inc.'s return on equity of -81.05%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B OMOutset Medical, Inc.39.38% -$1.00 $241M -
What do Analysts Say About VOR or OM?
Vor Biopharma, Inc. has a consensus price target of $43.25, signalling upside risk potential of 197.66%. On the other hand Outset Medical, Inc. has an analysts' consensus of $13.25 which suggests that it could grow by 302.74%. Given that Outset Medical, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Outset Medical, Inc. is more attractive than Vor Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.4 2 0 OMOutset Medical, Inc.3 1 0 -
Is VOR or OM More Risky?
Vor Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Outset Medical, Inc. has a beta of 2.030, suggesting its more volatile than the S&P 500 by 103.03%.
-
Which is a Better Dividend Stock VOR or OM?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Outset Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or OM?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Outset Medical, Inc. quarterly revenues of $29.4M. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Outset Medical, Inc.'s net income of -$17.8M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Outset Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 0.65x for Outset Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M OMOutset Medical, Inc.0.65x -- $29.4M -$17.8M
-
Which has Higher Returns VOR or SLRX?
Salarius Pharmaceuticals, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of --. Vor Biopharma, Inc.'s return on equity of -- beat Salarius Pharmaceuticals, Inc.'s return on equity of -316.09%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B SLRXSalarius Pharmaceuticals, Inc.-- -$1.81 $4.2M -
What do Analysts Say About VOR or SLRX?
Vor Biopharma, Inc. has a consensus price target of $43.25, signalling upside risk potential of 197.66%. On the other hand Salarius Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 61220.73%. Given that Salarius Pharmaceuticals, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Salarius Pharmaceuticals, Inc. is more attractive than Vor Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.4 2 0 SLRXSalarius Pharmaceuticals, Inc.0 0 0 -
Is VOR or SLRX More Risky?
Vor Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Salarius Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.225%.
-
Which is a Better Dividend Stock VOR or SLRX?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Salarius Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Salarius Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or SLRX?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Salarius Pharmaceuticals, Inc. quarterly revenues of --. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Salarius Pharmaceuticals, Inc.'s net income of -$873.5K. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Salarius Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus -- for Salarius Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M SLRXSalarius Pharmaceuticals, Inc.-- -- -- -$873.5K
-
Which has Higher Returns VOR or SNTI?
Senti Biosciences, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of --. Vor Biopharma, Inc.'s return on equity of -- beat Senti Biosciences, Inc.'s return on equity of -173.17%.
Company Gross Margin Earnings Per Share Invested Capital VORVor Biopharma, Inc.-- -$121.63 -$2.2B SNTISenti Biosciences, Inc.-- -$0.69 $38.2M -
What do Analysts Say About VOR or SNTI?
Vor Biopharma, Inc. has a consensus price target of $43.25, signalling upside risk potential of 197.66%. On the other hand Senti Biosciences, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 900%. Given that Senti Biosciences, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Vor Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VORVor Biopharma, Inc.4 2 0 SNTISenti Biosciences, Inc.3 0 0 -
Is VOR or SNTI More Risky?
Vor Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Senti Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VOR or SNTI?
Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Senti Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Senti Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VOR or SNTI?
Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Senti Biosciences, Inc. quarterly revenues of --. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Senti Biosciences, Inc.'s net income of -$18.1M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Senti Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 3.27x for Senti Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VORVor Biopharma, Inc.-- -- -- -$812.7M SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
